FGF21 and metabolic dysfunction-associated steatotic liver disease: We conducted a double-blind, randomized clinical trial to assess the effects of fish oil on lipid, glucose and other CVD risk factors, liver enzymes, NAFLD biomarkers such as FGF21 and CK18 fragment M30 (CK18-M30), and some inflammatory cytokines in adults with NAFLD associated with hyperlipidemia.